Fly News Breaks for March 5, 2020
Mar 5, 2020 | 08:14 EDT
Nomura Instinet analyst Christopher Marai sees a "catalyst rich" 2020 for Syndax Pharmaceuticals. The analyst keeps a Buy rating on the shares with a $16 price target post the company's Q4 results. The Phase 3 entinostat readout will bring share upside, whether positive or negative, as it will be a "clearing event," Marai tells investors in a research note. Post the readout, investors can refocus attention on Syndax's "well-regarded" Menin inhibitor SNDX-5613 and chronic graft versus host disease program, contends the analyst.
News For SNDX From the Last 2 Days
There are no results for your query SNDX